Skip to main content

Month: September 2024

Americold Realty Trust, Inc. Declares Third Quarter 2024 Dividend

ATLANTA, GA., Sept. 03, 2024 (GLOBE NEWSWIRE) — Americold Realty Trust (NYSE: COLD), a global leader in temperature-controlled logistics, real estate, and value-added services focused on the ownership, operation, acquisition and development of temperature-controlled warehouses, today announced that its Board of Directors has declared a dividend of $0.22 per share for the third quarter of 2024, payable to holders of the Company’s common stock. The dividend will be payable in cash on October 15, 2024 to stockholders of record at the close of business on September 30, 2024. About Americold Realty Trust, Inc. Americold is a global leader in temperature-controlled logistics real estate and value added services. Focused on the ownership, operation, acquisition and development of temperature-controlled warehouses, Americold owns and/or...

Continue reading

MiNK Therapeutics to Participate in H.C. Wainwright Global Investment Conference

NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) — MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that Dr. Jennifer Buell, Chief Executive Officer, will participate in a fireside chat and investor one-on-ones at the upcoming H.C. Wainwright 26th Annual Global Investment Conference on September 9-11th. The fireside chat will take place at 7:00 a.m. ET on Monday, September 9th. To access this event, please register at https://journey.ct.events/view/ad5300ce-fb6d-41fc-a276-ec783460f6d9. Following the event, a replay of the fireside chat will be posted to MiNK’s website at https://investor.minktherapeutics.com/events-and-presentations. About MiNK...

Continue reading

InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases

JENA, Germany, Sept. 03, 2024 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced the presentation of preclinical data for the company’s novel oral C5aR inhibitor, INF904, at the 2024 European Meeting on Complement in Human Diseases (EMCHD) being held in Lübeck, Germany, September 2 – 6, 2024. Members of InflaRx leadership also participated in a satellite symposium highlighting the role of the C5a/C5aR1 axis in driving inflammation and served as the biopharma industry representative on a panel focused on the relevance of targeting C3 and C5. InflaRx also hosted a lunch seminar focused on C5a/C5aR inhibition in human disease with best-in-class compounds. Camilla Chong, MD, Chief Medical Officer of InflaRx, commented:...

Continue reading

Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences

PURCHASE, N.Y., Sept. 03, 2024 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, today announced the Company’s president and CEO, Lisa Ricciardi will participate in two investor conferences in September. September 2024 Investor Conferences Event: Chardan Capital Markets Leadership Call    Date/Time: September 5, 2024, at 11:00am ETLivestream: Individuals interested in attending the live virtual event can email corpaccess@chardan.com Event: H.C. Wainwright 26th Annual Global Investment Conference   Date/Time: September 9-11, 2024 Webcast: Available On-Demand beginning September 9th at 7:00am ET “We recently presented results from the Phase 2, proof-of-concept, SHINE study showing our orally delivered CT1812...

Continue reading

Invesco Ltd: Form 8.3 -Rightmove PLC; Opening Position Disclosure

FORM 8.3 OPENING POSITION DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)1. KEY INFORMATION     (a) Full name of discloser: Invesco Ltd.  (b) Owner or controller of interests and short positions disclosed, if different from 1(a):The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.    (c) Name of offeror/offeree in relation to whose relevant securities this form relates:Use a separate form for each offeror/offeree Rightmove PLC  (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:    (e) Date position held/dealing undertaken:For an opening position disclosure, state the latest practicable date prior to...

Continue reading

GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates

Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024 and expected completion of 6-month open-label extension phase in Q1 2025 Phase 1 clinical trial to evaluate proprietary aerosol delivery device in healthy adult subjects approved in the UK and recruiting Cash, cash equivalents, other financial assets and marketable securities of $204.5 millionDUBLIN, Sept. 03, 2024 (GLOBE NEWSWIRE) — GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the second quarter ended June 30, 2024, and provided updates on its business. Business Updates We announced today, in a separate press release, the promotion...

Continue reading

Auddia Announces Integration of faidr Into Apple CarPlay and Android Auto

BOULDER, CO, Sept. 03, 2024 (GLOBE NEWSWIRE) — More Than 90% of New Vehicles Now Offer Apple CarPlay or Android Auto and Will Have Access to faidr’s AI Technology When Apple CarPlay or Android Auto are Available More Than 50% of All Audio Listening is to AM/FM and Podcasts   {{DATELINECITY_DATE_GLOBENEWSWIRE_BUG} Auddia Inc. (NASDAQ:AUUD) (NASDAQ:AUUDW) (“Auddia” or the “Company”), a proprietary AI platform for audio identification and classification and related technologies, reinventing how consumers engage with AM/FM radio, podcasts, and other audio content, today announced it recently launched both Apple CarPlay and Android Auto interfaces for its faidr mobile application. These interfaces allow consumers to mirror their smartphone entertainment options on the screen of their vehicle’s infotainment system. Apple CarPlay and...

Continue reading

The Ensign Group Adds Seven New Operations in Colorado

SAN JUAN CAPISTRANO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) — The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living services, physical, occupational and speech therapies, other rehabilitative and healthcare services, and real estate, announced today that it acquired the operations of the following skilled nursing facilities in Colorado:Desert Willow Health and Rehabilitation Center, a 106-bed skilled nursing facility located in Pueblo, Colorado; Junction Creek Health and Rehabilitation Center, a 133-bed skilled nursing facility located in Durango, Colorado; Pelican Pointe Health and Rehabilitation Center, a 104-bed skilled nursing facility located in Windsor, Colorado; Riverbend Health and Rehabilitation Center, a 100-bed...

Continue reading

The Ensign Group Acquires New Operation in Kansas

SAN JUAN CAPISTRANO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) — The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living services, physical, occupational and speech therapies, other rehabilitative and healthcare services, and real estate, announced today that it acquired the operations of Prairie Ridge Health and Rehabilitation, a 102-bed skilled nursing facility located in Overland Park, Kansas. This acquisition was effective as of September 1, 2024, and is subject to a long-term, triple net lease. “This operation is another tremendous facility in Kansas, where we have been experiencing fantastic growth over the past year,” said Barry Port, Ensign’s Chief Executive Officer. Dave Jorgensen, President of Gateway Healthcare...

Continue reading

Woodbridge International Closes Sale of Duroair Technologies Inc. to Nederman

NEW HAVEN, Conn., Sept. 03, 2024 (GLOBE NEWSWIRE) — Woodbridge International, a global mergers and acquisitions firm, is pleased to announce the acquisition of its client, Duroair Technologies Inc. by Nederman. Duroair, headquartered in Niagara Falls, Ontario, Canada holds a unique market position in designing, manufacturing and selling climate controlled air filtration with US and Canada as the main markets. Duroair’s unique and flexible enclosures and filtration systems trap and extract fumes, dust and gases created by coating, grinding, sanding and adhesive bonding processes. The company has a strong position within the defense, aerospace and industrial manufacturing industries, including mitigation of hexavalent chromium. Nederman is an environmental technology company and a global leader in industrial air filtration dedicated...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.